Document Detail

Chemotherapy administration: modelling the costs of alternative protocols.
MedLine Citation:
PMID:  23148697     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: The increasing cost of chemotherapy is placing greater pressures on limited healthcare budgets. A potentially important, but often overlooked, aspect of chemotherapy is the cost associated with administration. This study aims to develop a better understanding of these costs, and in doing so, develop a model to estimate the comparative cost of administering alternative chemotherapy protocols for economic evaluation or local decision making.
METHODS: We identified the potential tasks and choices related to administering intravenous chemotherapy, grouped tasks according to anticipated resource use, and allocated costs to each task using data from an evidence-based collection of cancer protocols or from primary data collection. The resources were costed from a healthcare system perspective using standard data sources within Australia. The model was applied to alternative protocols used in the treatment of three different cancers: locally advanced and metastatic non-small-cell lung cancer, adjuvant colorectal cancer and adjuvant breast cancer.
RESULTS: For the three cancer types examined, the cost of completed administration ranged from 1274 Australian dollars ($A) to $A3015 (year 2009 values) for 13 different protocols potentially used for the initial treatment of locally advanced and metastatic non-small-cell lung cancer; $A5175-8445 for seven protocols for adjuvant colorectal cancer treatment; and $A1494-4074 for seven protocols for adjuvant breast cancer treatment.
CONCLUSIONS: The results are of practical significance to those undertaking economic evaluations and to decision makers who use this information within the area of chemotherapy. The examples used suggest that administration costs per visit varied inversely with the number of visits. The results provide information where little has previously been available and may allow decisions about costs and resource allocation to be made with more certainty. Although our model uses costs from the public health system within an Australian state (New South Wales), it can be adapted for use in other jurisdictions.
Philip Haywood; Johan de Raad; Kees van Gool; Marion Haas; Gisselle Gallego; Sallie-Anne Pearson; Margaret Faedo; Robyn Ward
Related Documents :
24114497 - Cancer incidence and mortality patterns in women with anorexia nervosa.
24175827 - Estimation of esophageal cancer incidence in tehran by log- linear method using populat...
23936237 - Breast cancer survival in germany: a population-based high resolution study from saarland.
23660117 - Recruiting women for a study on perceived risk of cancer: influence of survey topic sal...
21140477 - A systematic review of studies on psychosocial late effects of childhood cancer: struct...
22847987 - Update and external validation of a head and neck cancer prognostic model.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  PharmacoEconomics     Volume:  30     ISSN:  1179-2027     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-11-12     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1173-86     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravenous
Antineoplastic Agents / administration & dosage,  economics,  therapeutic use*
Breast Neoplasms / drug therapy,  economics,  pathology
Carcinoma, Non-Small-Cell Lung / drug therapy,  economics,  pathology
Chemotherapy, Adjuvant / economics,  methods
Colorectal Neoplasms / drug therapy,  economics,  pathology
Decision Making*
Drug Costs
Lung Neoplasms / drug therapy,  economics,  pathology
Models, Economic*
Neoplasm Metastasis
New South Wales
Grant Support
455366//Medical Research Council
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Systemic thromboembolism after anti-cancer chemotherapy in a woman with ovarian germ cell tumor.
Next Document:  Estimating the Contributions of Associations and Recoding in the Implicit Association Test: The ReAL...